New diabetes drug candidate passes first safety check in healthy volunteers
NCT ID NCT05147259
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested the safety and how the body processes a new drug called HR011408 in 62 healthy adults. Participants received two different versions of the drug to compare them. The goal was to check for side effects and measure drug levels in the blood, not to treat diabetes. This is a first step before testing in people with diabetes.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- HR011408 injection
- What this could lead to
- If successful, this could help develop a new treatment option for diabetes.
- What could go wrong
- This is an early Phase 1 trial in healthy people, not patients. It only tests safety and drug levels, not whether it works for diabetes. Many drugs fail in later stages.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
62 people
The number who actually took part.
- Started
-
Nov 2021
- Finished
-
Jan 2022
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male or female aged 18-55 years (both inclusive) at the time of signing informed consent. 2. Body mass index 18.0-26.0kg/m2 (both inclusive). 3. Body weight ≥ 50.0 kg (male),≥ 45.0 kg (female). 4. Fasting serum/plasma glucose \< 6.1 mmol/L. Exclusion Criteria: 1. Known or suspected of being allergic to any ingredient in the study drug. 2. Participated in any drug or medical device-related clinical trial within 3 months before screening. 3. Subjects addicted to smoking, or non-smoker who smoked within 48 hours before administration. 4. Donated blood within 1 month before screening; or donated blood ≥ 400 mL or had blood loss ≥ 400 mL during trauma or major surgery within 3 months before screening. 5. Subjects with incompetence or language impairment, who cannot fully understand or participate in the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetes in adults are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shandong Provincial Qianfoshan Hospital
Jinan, Shandong, 250014, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.